guest ::
| Home > Publications database > Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach. > print |
| Home > Publications database > Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach. > print |
| 001 | 182306 | ||
| 005 | 20240229145715.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers14205128 |2 doi |
| 024 | 7 | _ | |a pmid:36291912 |2 pmid |
| 024 | 7 | _ | |a altmetric:137663277 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02563 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Slavc, Irene |0 0000-0002-9419-6790 |b 0 |
| 245 | _ | _ | |a Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach. |
| 260 | _ | _ | |a Basel |c 2022 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667214769_18730 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Medulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis at different levels. We report on a novel combinatorial metronomic antiangiogenic approach. The study is a retrospective observational study of 29 consecutive patients with first or multiple recurrences prospectively treated according to the MEMMAT strategy ('MEMMAT-like') before the formal protocol (MEMMAT; ClinicalTrials.gov Identifier: NCT01356290) started. The study period was 11/2006 to 06/2016. Treatment consisted of daily oral thalidomide, fenofibrate, celecoxib, and alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide supplemented by IV bevacizumab and intraventricular therapy consisting of alternating etoposide and liposomal cytarabine. Median overall survival (OS) after recurrence for the whole group was 29.5 months, OS was 48.3 ± 9.3% at three years and 34.5 ± 8.8% at five years, and progression-free survival was 42.0 ± 9.5% at three years and 29.4 ± 9% at five years. As of 07/2022, 9/29 patients are alive 86 to 164 months after the recurrence that prompted the 'MEMMAT-like' therapy. Treatment was primarily out-patient and generally well-tolerated. Toxicities did occur but were manageable. In conclusion, antiangiogenic therapy according to the MEMMAT strategy increased median OS of patients with recurrent MB and may lead to long-term survival. Adherence to the protocol, including intraventricular therapy, appears important. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a MEMMAT |2 Other |
| 650 | _ | 7 | |a antiangiogenic therapy |2 Other |
| 650 | _ | 7 | |a bevacizumab |2 Other |
| 650 | _ | 7 | |a intraventricular therapy |2 Other |
| 650 | _ | 7 | |a low-dose oral therapy |2 Other |
| 650 | _ | 7 | |a medulloblastoma recurrence |2 Other |
| 650 | _ | 7 | |a metronomic therapy |2 Other |
| 700 | 1 | _ | |a Mayr, Lisa |0 0000-0002-6841-0749 |b 1 |
| 700 | 1 | _ | |a Stepien, Natalia |b 2 |
| 700 | 1 | _ | |a Gojo, Johannes |b 3 |
| 700 | 1 | _ | |a Aliotti Lippolis, Maria |b 4 |
| 700 | 1 | _ | |a Azizi, Amedeo A |b 5 |
| 700 | 1 | _ | |a Chocholous, Monika |b 6 |
| 700 | 1 | _ | |a Baumgartner, Alicia |0 0000-0002-0894-4167 |b 7 |
| 700 | 1 | _ | |a Hedrich, Cora S |b 8 |
| 700 | 1 | _ | |a Holm, Stefan |b 9 |
| 700 | 1 | _ | |a Sehested, Astrid |b 10 |
| 700 | 1 | _ | |a Leblond, Pierre |0 0000-0002-7088-2614 |b 11 |
| 700 | 1 | _ | |a Dieckmann, Karin |b 12 |
| 700 | 1 | _ | |a Haberler, Christine |0 0000-0003-1016-0545 |b 13 |
| 700 | 1 | _ | |a Czech, Thomas |0 0000-0001-8112-2795 |b 14 |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 15 |u dkfz |
| 700 | 1 | _ | |a Peyrl, Andreas |0 0000-0002-5736-8231 |b 16 |
| 773 | _ | _ | |a 10.3390/cancers14205128 |g Vol. 14, no. 20, p. 5128 - |0 PERI:(DE-600)2527080-1 |n 20 |p 5128 |t Cancers |v 14 |y 2022 |x 2072-6694 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:182306 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|